Clinical trials: Ticagrelor
Coronary Artery Disease, Peripheral Arterial Disease
Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Conditions
- Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation
- Trial name
- NCT03718429
- Testing
- Rivaroxaban 2.5 mg Tablet
- Where
- 2 sites in United States
- Volunteers
- 86 people
- Sponsor
- University of Florida
High Ischemic Risk
24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes between aspirin with ticagrelor versus aspirin with clopidogrel in high ischemic risk patients beyond 12 months after percutaneous…
- Trial name
- NCT04989257
- Testing
- Ticagrelor-based dual-antiplatelet therapy, Clopidogrel-based dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,488 people
- Sponsor
- Yonsei University
Ischemic Stroke
Ticagrelor Versus Cilostazol in Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever moderate and moderate to severe ischemic stroke compared to 200 mg cilostazol…
- Trial name
- NCT06561867
- Testing
- Ticagrelor 90 MG, Cilostazol 100 MG
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
ST Segment Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI
In STEMI patients undergoing PPCI there is a delayed onset of action of oral P2Y12 receptor inhibitors, including prasugrel and ticagrelor.
- Trial name
- CANTIC (NCT03247738)
- Testing
- Cangrelor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Florida
Acute Myocardial Infarction
TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI
The purpose of this study is to evaluate the efficacy and safety of clopidogrel in stabilized patients with acute myocardial infarction (AMI) who performed percutaneous coronary intervention (PCI) with drug-eluting stents (DES)…
- Trial name
- NCT02018055
- Testing
- Aspirin+Ticagrelor, Aspirin+Clopidogrel
- Where
- South Korea
- Volunteers
- 2,590 people
- Sponsor
- The Catholic University of Korea
Coronary Artery Disease
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention.
- Trial name
- SWAP-7 (NCT06691191)
- Testing
- Ticagrelor 90 mg, Prasugrel 10 mg
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Florida
Acute Coronary Syndrome:, Non ST Elevation Myocardial Infarction
Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel
The administration of these drugs is realized according to the European Society of Cardiology guidelines. All patients will be pretreated with aspirin 300 mg orally, heparin iv to maintain an activated clotting time of >250 sec…
- Conditions
- Acute Coronary Syndrome:, Non ST Elevation Myocardial Infarction, ST Elevation Myocardial Infarction, Unstable Angina
- Trial name
- NCT02032290
- Testing
- Assessment of Coronary Flow Reserve, Percutaneous coronary intervention, ticagrelor loading
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- Azienda Policlinico Umberto I
Acute Coronary Syndrome
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
East Asian patients will be required optimal dose of newer P2Y12 inhibitors (prasugrel or ticagrelor) to determine the safer treatment and better outcome.
- Trial name
- NCT02944123
- Testing
- Clopidogrel 75 mg, Prasugrel 5 mg, Ticagrelor 45 mg
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Dong-A University
Platelet Reactivity
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients with coronary artery disease, but these benefits come at the expense of increased risk of bleeding when compared with…
- Trial name
- NCT04001894
- Testing
- Ticagrelor 90mg, Clopidogrel 75mg
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Coronary Artery Disease
Reversing Ticagrelor's Effects With Fresh Platelets
Acute coronary syndrome (ACS) patients treated with antiplatelet drugs who require coronary artery bypass grafting (CABG) surgery have to wait 5-7 days for the effects of the drugs to wean off.
- Trial name
- NCT02201394
- Testing
- Ticagrelor loading dose, Aspirin loading dose, Ticagrelor maintenance dose
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Severe Aortic Valve Stenosis, Transcatheter Aortic Valve Implantation
Platelet Reactivity After TAVI: A Multicenter Pilot Study
A high platelet reactivity in patients with severe symptomatic Aortic Stenosis (AS) selected for TAVI (Transcatheter aortic valve implantation) procedure has been demonstrated previously, and the use of double antiaggregation…
- Conditions
- Severe Aortic Valve Stenosis, Transcatheter Aortic Valve Implantation, Transcatheter Aortic Valve Replacement
- Trial name
- REAC-TAVI (NCT02224066)
- Testing
- Ticagrelor 90 mg twice per day during three months following TAVI, Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI
- Where
- 7 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Hospital de Meixoeiro
Cerebrovascular Accident, Cerebrovascular Accident, Acute
Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke
Cerebrovascular disease is the main cause of death and severe long-term disability worldwide. Antiplatelet drugs are the main drugs for ischemic stroke and TIA.
- Trial name
- NCT04962451
- Testing
- ticagrelor + ASA
- Where
- China
- Volunteers
- 13,000 people
- Sponsor
- Peking University Third Hospital
Peripheral Artery Disease, Type 2 Diabetes
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
The hypothesis being that both aspirin-ticagrelor and ticagrelor monotherapy will be superior to aspirin monotherapy in the reduction of whole blood viscosity at the end of each 4 week treatment period.
- Trial name
- NCT02325466
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Coronary Artery Disease
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Numerous studies have shown that pharmacodynamics (PD) response profiles vary among clopidogrel treated patients and that individuals with reduced response have an increased risk of recurrent ischemic events.
- Trial name
- NCT02065479
- Testing
- Prasugrel, Ticagrelor
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Florida
Coronary Artery Disease, Stable Angina
Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG
The primary objective of this study ist to test the hypothesis that ticagrelor is superior to Aspirin (ASA) fort he prevention of major cardio- and cerebrovascular events (MACCE) in patients undergoing artery bypass operation.
- Conditions
- Coronary Artery Disease, Stable Angina, Acute Coronary Syndrome
- Trial name
- TiCAB (NCT01755520)
- Testing
- Ticagrelor, Aspirin
- Where
- 29 sites in Austria, Germany and 1 more
- Volunteers
- 1,893 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Individualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention
Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI
Background:Diabetes and smoking are common factors found to increase platelet reactivity in patients undergoing primary PCI. Objective: Compare the individualized and combined effects of smoking and diabetes on the antiplatelet…
- Trial name
- NCT05911659
- Testing
- Ticagrelor
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mina Wageh Mohareb
Pneumonia, Community Acquired Pneumonia
Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor
The hypothesis to be tested is that ticagrelor (Brilinta™) will reduce platelet activation and markers of inflammation in patients with pneumonia.
- Conditions
- Pneumonia, Community Acquired Pneumonia, Hospital Acquired Pneumonia, Acute Lung Injury
- Trial name
- XANTHIPPE (NCT01883869)
- Testing
- ticagrelor
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Kentucky
Coronary Artery Disease, Diabetes Mellitus
Clopidogrel Versus Ticagrelor in Type-2 Diabetes
CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2…
- Trial name
- NCT02742987
- Testing
- Ticagrelor, Clopidogrel, Standard medical therapy
- Volunteers
- 42 people
- Sponsor
- Campus Bio-Medico University
Coronary Artery Disease
Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor
The administration of Ticagrelor have demonstrated superiority to Clopidogrel in patients presenting with acute coronary syndrome (ACS) and remains a first line therapy as an adjunct to aspirin for patients admitted with ACS.
- Trial name
- CABG-TIME (NCT02627521)
- Testing
- PRU guided CABG, CABG per standard of care, VerifyNow assay
- Where
- Canada
- Volunteers
- 260 people
- Sponsor
- Unity Health Toronto
STEMI, STEMI - ST Elevation Myocardial Infarction
The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor
Fast and accurate platelet inhibition is an important therapeutic goal in the acute treatment of patients with ST-segment elevation myocardial infarction (STEMI).
- Trial name
- ON-TIME 3 (NCT03400267)
- Testing
- Paracetamol, Fentanyl
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- A.H. Tavenier